← Human Trials & Peer-Reviewed Studies
Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes
Plain-language guide to PMID 33710717 (2021): double-blind randomized controlled trial study of Semaglutide.
Key Facts
- PMID
- 33710717
- Journal
- Diabetes, obesity & metabolism
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Dahl K et al. (6 authors)
- DOI
- 10.1111/dom.14373
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Semaglutide.
To assess the effects of oral semaglutide on postprandial glucose and lipid metabolism, and gastric emptying, in subjects with type 2 diabetes (T2D).
Who Took Part
The age groups tagged for this paper are middle-aged adults, men only.
Glucose and lipid metabolism, and gastric emptying (paracetamol absorption) were assessed before and after two types of standardized meals (standard and/or fat-rich) at the end of each treatment period.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and crossover study.
Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Semaglutide group a baseline to be compared against.
Each person switched between Semaglutide and the comparison at some point, usually with a gap in between.
The primary endpoint was area under the glucose 0-5-h curve (AUC0-5h ) after the standard breakfast.
What Was Measured
PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Gastric Emptying, Glucagon-Like Peptides, Glucose, Hypoglycemic Agents and Lipid Metabolism.
Author keywords: GLP-1 analogue, dyslipidaemia, glycaemic control, incretin therapy and type 2 diabetes.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Semaglutide.
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2021 (Diabetes, obesity & metabolism), a journal based in England.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.